Non- Invasive Initiation & Monitoring of Resmetirom (RT) Therapy Using LIVERFASt, FIB-4, and VCTE in MASH Patients
The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom (RT) therapy […]
Publication
LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients
In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4
The Utility of Non-Invasive Tests (NITs) – LIVERFASt, FIB4 and VCTE (Fibroscan) in MASH Patients
This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy.
Association between Psoriasis Severity & Steatosis Measured by AI-based Algorithm (LIVERFAStTM)
This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe
Combination of LIVERSTAT (LST) and Fibroscan (LSM) Outperforms FIB-4 and LSM for MASLD Advanced Fibrosis
Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those
Combination of LIVERfASt (LF) & Liver Stiffness Measurement (LSM) in patients with type 2 diabetes (T2D)
Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in
LIVERFASt: Non-Invasive Liver Assessment for Chronic Hepatitis B & Diabetes
This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and
Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies’ populations using liver biopsy
MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis
Application of LIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure
Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents
Comparison of the prevalence of advanced fibrosis (AF) using two combinations: Liver stiffness measurement (LSM or VCTE Fibroscan) along with LIVERSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort
AI-based blood tests LIVERSTAT for advanced fibrosis (AF) in patients with T2D can streamline the diagnostic process. Aim of this